Coave Therapeutics closes Series B

Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.

Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million. The investors include Seroba Life Sciences, Théa Open Innovation, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest and GO Capital.

Source: Press Release